Zalutumumab
Sponsors
Genmab, Danish Head and Neck Cancer Group
Conditions
Cancer of the Head and NeckColorectal CancerHead and Neck CancerHead and Neck NeoplasmsNon Small Cell Lung CancerNon-small Cell Lung CancerSquamous Cell CancerSquamous Cell Carcinoma
Phase 1
Zalutumumab in Head and Neck Cancer
CompletedNCT00093041
Start: 2003-12-01End: 2005-01-12Updated: 2023-06-28
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
TerminatedNCT00401401
Start: 2006-12-31End: 2010-10-31Updated: 2011-12-23
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
TerminatedNCT00677924
Start: 2008-04-30End: 2009-04-30Updated: 2023-07-18
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
TerminatedNCT00707655
Start: 2008-09-30End: 2010-10-31Updated: 2023-08-03
Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
CompletedNCT01054625
Start: 2010-03-31End: 2011-10-31Updated: 2023-08-03
Phase 2
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
TerminatedNCT00460551
Start: 2007-04-30End: 2008-10-31Updated: 2011-12-06
Zalutumumab in Non-curable Patients With SCCHN
CompletedNCT00542308
Start: 2008-01-31End: 2011-08-31Updated: 2023-08-03
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
WithdrawnNCT01449357
Updated: 2011-10-10
Phase 3
Zalutumumab in Patients With Non-curable Head and Neck Cancer
CompletedNCT00382031
Start: 2006-11-30End: 2011-08-31Updated: 2013-10-15
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
CompletedNCT00496652
Start: 2007-11-30End: 2016-11-30Updated: 2016-11-25